You are about to leave the Clinical Value website now.

Cancel

Screening for Liver Cancer at Zhuhai People’s Hospital

Dr Bing Liu discusses the outcomes of Project Pearl, an end-to-end liver disease management project, at Zhuhai People’s Hospital

Interview transcript:

Introduction

Hi everyone. My name is Bing Liu. I’m an interventional radiologist. I got my PhD at Heidelburg University Germany, and then finished my training as postdoc at Yale University. And then I work at Zhuhai People’s Hospital, also as a member of Zhuhai Project Pearl until April this year. And now I’m working at Guangzhou First People’s Hospital.

About Project Pearl

Project Pearl is a collaboration between Zhuhai Hospital and Roche to transform liver disease care in China through holistic, end-to-end management.

By integrating advanced diagnostics, streamlined workflows, and digital tools, it addresses challenges in hepatocellular carcinoma (HCC) care. The project focuses on early detection, personalized risk stratification, and continuous follow-up, improving patient outcomes and empowering clinicians with data-driven insights.

To date, thousands of patients are enrolled and the program shows high rates of early-stage HCC detection.

What is the current liver disease landscape in China and what is Zhuhai doing to improve HCC screening?

We all know that China has a huge burden of liver cancer accounting for over 40% of the new cases and death cases around the world. As we have already accumulated a lot of experience in our Project Pearl, we know clearly what improvements we can make in the future. We are now trying to upgrade our screening modalities, especially the patient follow-up module.

What were the key outcomes of Project Pearl?

Up to now, we have finished screening and risk assessments in 5,122 patients and 41 of them were diagnosed with HCC; the percentage was 0.8%. And besides the early diagnosis rate of HCC was reported as 30% in our country, while, in our Zhuhai project, 39 of the 41 HCC patients were diagnosed with early-stage HCC and the early diagnosis rate of HCC was 95%, which means our project has greatly improved the early diagnosis rate of HCC. For the patients diagnosed with HCC, after our MDT discussion, all of them finally received optimal treatments in Zhuhai People’s Hospital.

How has the implementation of digital solutions influenced your overall clinical workflow?

Digital solutions are great assistants to our clinicians, especially inpatient registration, data collection, data analysis, and risk assessment, it’s indeed increased the efficiency of screening and decision-making.

Based on the project outcomes, what recommendations do you have for other APAC clinicians regarding the implementation of digital solutions in their institute?

It is an artificial intelligence century now, and we have to admit that many high-techs are changing our lifestyle. Therefore, I recommend our clinicians to embrace digital solutions to grow with them. And trust me, they will finally become excellent assistants to us.

The views and opinions expressed by Dr. Bing Liu are his own views and opinions. Roche disclaims all liability in relation to these views and opinions.

You May Also Like

27 June 2024

Cost-Utility of Novel Biomarker-Based Strategies for Hepatocellular Carcinoma (HCC) Surveillance in Thailand

Read More

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.